Investment firm Bain Capital has bought Japanese company Mitsubishi Tanabe Pharma Corporation in a $3.3bn deal. Tanabe Pharma had revenue of approximately $2.89bn during the fiscal year ending 31 March 2024, an 18.3% decrease from the previous fiscal year. Its R&D spending of around $415.5m was more than that of all other Mitsubishi Chemical Group divisions combined. The purchase gives Bain access to a variety of products and a drug pipeline across various key therapeutic areas.
Single-sex ward rule broken hundreds of times at the Royal Free
A law preventing mixed-sex patient wards in the NHS was violated 537 times by the Royal Free London in the 12 months to November 2021.
